HER2 missense mutations have distinct effects on oncogenic signaling and migration

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 45, 2015, Pages E6205-E6214

  Zabransky, Daniel J ^a   Yankaskas, Christopher L ^b   Cochran, Rory L ^a   Wong, Hong Yuen ^a   Croessmann, Sarah ^a   Chu, David ^a   Kavuri, Shyam M ^c,g   Brewer, Monica Red ^d   Marc Rosen, D ^a   Brian Dalton, W ^a   Cimino Mathews, Ashley ^a,e   Cravero, Karen ^a   Button, Berry ^a   Kyker Snowman, Kelly ^a   Cidado, Justin ^a,h   Erlanger, Bracha ^a   Parsons, Heather A ^a,b   Manto, Kristen M ^b   Bose, Ron ^c,d   Lauring, Josh ^a   Arteaga, Carlos L ^d   Konstantopoulos, Konstantinos ^b,f   Park, Ben Ho ^a,b   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f Washington University in St Louis School of Medicine   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LAPATINIB; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; NVP-BYL719; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

BREAST EPITHELIUM CELL; CARCINOGENESIS; CARCINOGENICITY; CONFERENCE PAPER; GENE LOCUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; CELL MOTION; CELL PROLIFERATION; CFU COUNTING; FLOW CYTOMETRY; GENE TARGETING; GENETICS; HEK293 CELL LINE; IMMUNOBLOTTING; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; GENE TARGETING; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MUTATION, MISSENSE; NEOPLASMS; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 84946763302     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1516853112     Document Type: Article

References (36)

1. Arteaga CL, Engelman JA (2014) ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282-303.
2. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137.
3. Ellis MJ, et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353-360.
4. Bose R, et al. (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3(2):224-237.
5. Shah SP, et al. (2012) The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 486(7403):395-399.
6. Lee JW, et al. (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12(1):57-61.
7. Greulich H, et al. (2012) Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 109(36):14476-14481.
8. Rexer BN, et al. (2013) Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res 19(19):5390-5401.
9. Wang SE, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10(1):25-38.
10. Trowe T, et al. (2008) EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14(8):2465-2475.
11. Konishi H, et al. (2007) Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 67(18):8460-8467.
12. Lauring J, et al. (2010) Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 29(16):2337-2345.
13. Di Nicolantonio F, et al. (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci USA 105(52):20864-20869.
14. Wang GM, et al. (2013) Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res 73(11): 3248-3261.
15. Subik K, et al. (2010) The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 4:35-41.
16. Soule HD, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50(18):6075-6086.
17. Gustin JP, et al. (2009) Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 106(8):2835-2840.
18. Kancha RK, et al. (2011) Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One 6(10):e26760.
19. Beaver JA, et al. (2013) PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res 19(19):5413-5422.
20. Gabelli SB, et al. (2014) Activation of PI3Kα by physiological effectors and by oncogenic mutations: Structural and dynamic effects. Biophys Rev 6(1):89-95.
21. Masuda H, et al. (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331-345.
22. Hart JR, et al. (2015) The butterfly effect in cancer: A single base mutation can remodel the cell. Proc Natl Acad Sci USA 112(4):1131-1136.
23. Balzer EM, et al. (2012) Physical confinement alters tumor cell adhesion and migration phenotypes. FASEB J 26(10):4045-4056.
24. Tong Z, et al. (2012) Chemotaxis of cell populations through confined spaces at singlecell resolution. PLoS One 7(1):e29211.
25. Hung W-C, et al. (2013) Distinct signaling mechanisms regulate migration in unconfined versus confined spaces. J Cell Biol 202(5):807-824.
26. Stroka KM, Konstantopoulos K (2014) Physical biology in cancer. 4. Physical cues guide tumor cell adhesion and migration. Am J Physiol Cell Physiol 306(2): C98-C109.
27. Li N, et al. (2011) Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci USA 108(31):12851-12856.
28. Barkan D, et al. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68(15):6241-6250.
29. Chakrabarty A, et al. (2010) H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29(37):5193-5203.
30. Blair BG, et al. (2015) A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics 15(2-3):318-326.
31. Yang B, Zhang H, Wang H (2015) Atomistic insights into the lung cancer-Associated L755P mutation in HER2 resistance to lapatinib: A molecular dynamics study. JMol Model 21(2):24.
32. Jaiswal BS, et al. (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23(5):603-617.
33. Yi KH, Axtmayer J, Gustin JP, Rajpurohit A, Lauring J (2013) Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: Implications for personalized medicine. Oncotarget 4(1):29-34.
34. Network CGA; Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
35. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30(3):256-268.
36. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.